tiprankstipranks
Advertisement
Advertisement

RARE Stock Latest News

Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
The FlyHemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
1d ago
DYN
RNA
Ultragenyx BLA for UX111 Accepted for FDA Review
PremiumCompany Announcements
Ultragenyx BLA for UX111 Accepted for FDA Review
12d ago
8K
RARE
Ultragenyx UX111 AAV9 biologics license application accepted for FDA review
PremiumThe Fly
Ultragenyx UX111 AAV9 biologics license application accepted for FDA review
12d ago
RARE
Ultragenyx Wins FDA IND Clearance for UX016 Therapy
PremiumCompany Announcements
Ultragenyx Wins FDA IND Clearance for UX016 Therapy
15d ago
8K
RARE
Ultragenyx announces FDA clearance of UX016 investigational new drug application
PremiumThe Fly
Ultragenyx announces FDA clearance of UX016 investigational new drug application
15d ago
RARE
Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa
PremiumCompany AnnouncementsUltragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa
20d ago
RARE
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
Premium
The Fly
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
21d ago
EL
RL
Microsoft reinstated, Ralph Lauren upgraded: Wall Street’s top analyst calls
Premium
The Fly
Microsoft reinstated, Ralph Lauren upgraded: Wall Street’s top analyst calls
21d ago
RL
AJG
Shareholders Sue Mereo BioPharma (MREO) Over Brittle Bone Drug Claims
PremiumMarket News
Shareholders Sue Mereo BioPharma (MREO) Over Brittle Bone Drug Claims
21d ago
NVS
MREO
Ultragenyx downgraded to Neutral from Buy at Goldman Sachs
PremiumThe Fly
Ultragenyx downgraded to Neutral from Buy at Goldman Sachs
21d ago
RARE
Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims
PremiumMarket News
Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims
27d ago
RARE
Ultragenyx Announces Positive Phase 3 Results for DTX301
PremiumCompany Announcements
Ultragenyx Announces Positive Phase 3 Results for DTX301
1M ago
8K
RARE
Ultragenyx Phase 3 Enh3ance study showed statistically significant results
PremiumThe FlyUltragenyx Phase 3 Enh3ance study showed statistically significant results
1M ago
RARE
Ultragenyx price target lowered to $74 from $120 at JPMorgan
Premium
The Fly
Ultragenyx price target lowered to $74 from $120 at JPMorgan
1M ago
RARE
Controversial Prasad leaving FDA, NYT reports
Premium
The Fly
Controversial Prasad leaving FDA, NYT reports
1M ago
AZN
BMY
Ultragenyx Pharmaceutical Faces Investor Lawsuit Following Study Failures and Stock Decline
PremiumClass Action
Ultragenyx Pharmaceutical Faces Investor Lawsuit Following Study Failures and Stock Decline
2M ago
RARE
Ultragenyx Gains FDA Priority Review for DTX401 Therapy
PremiumCompany Announcements
Ultragenyx Gains FDA Priority Review for DTX401 Therapy
2M ago
8K
RARE
Ultragenyx announces U.S. FDA accepted for review BLA for DTX401 AAV
PremiumThe Fly
Ultragenyx announces U.S. FDA accepted for review BLA for DTX401 AAV
2M ago
RARE
Ultragenyx price target lowered to $34 from $37 at Evercore ISI
PremiumThe Fly
Ultragenyx price target lowered to $34 from $37 at Evercore ISI
2M ago
RARE
Ultragenyx price target lowered to $79 from $128 at Canaccord
PremiumThe FlyUltragenyx price target lowered to $79 from $128 at Canaccord
2M ago
RARE
Ultragenyx price target lowered to $37 from $39 at Evercore ISI
Premium
The Fly
Ultragenyx price target lowered to $37 from $39 at Evercore ISI
2M ago
RARE
Ultragenyx price target lowered to $50 from $60 at H.C. Wainwright
Premium
The Fly
Ultragenyx price target lowered to $50 from $60 at H.C. Wainwright
2M ago
RARE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >